STAT June 24, 2024
On top of today’s Alnylam news, we have Congress gearing up to vote on Medicare coverage for multi-cancer screenings and obesity drug coverage. Also, updates on Vertex’s type 1 diabetes cell therapy, and a push for phage therapy.
Alnylam’s highly anticipated readout
Alnylam this morning reported highly anticipated topline results of its HELIOS-B trial testing vutrisiran in an increasingly common heart condition called ATTR-CM. Here are the findings:
Vutrisiran cut the risk of death and recurrent cardiovascular complications by 28% vs. placebo in the overall trial population, which included people who were taking the standard of care treatment (a drug from Pfizer called Vyndaqel/Vyndamax). In a subpopulation of patients who were not on that background treatment, or the monotherapy population,...
Today's Sponsors
Today's Sponsor